CTAG was established through discussion between Drugs and Therapeutics Committees, Area Prescribing Committees and specialists to provide advice and support in the management of COVID-19 whilst national guidelines evolve.
Its intention is to bring together national advice from:
- Medicines and Healthcare products Regulatory Agency (MHRA)
- National Institute for Health Research (NIHR)
- Chief Medical Officers’ (CMO) offices
- NHS England (NHSE)
- National Institute for Health and Care Excellence (NICE)
- Scottish Medicines Consortium (SMC)
- All Wales Medicines Strategy Group (AWMSG)
CTAG is the parent group for two key subgroups, each with specialist membership from UK NHS provider sites. Each subgroup acts as a specialist panel for discussion and consensus on medicines to be used for patients with COVID-19 both within and outside of a clinical trial, whilst taking into account advice from key national stakeholders.
- Antivirals; originally involving Infectious Diseases and Virology specialists from the High Consequence Infectious Diseases (HCID) Network, and subsequently expanded to include multidisciplinary representation from non-HCID NHS providers
- Immunomodulatory; drawing membership from the Hemophagocytic lymphohistiocytosis Across Specialities Collaboration (HASC), a group already formed for management and research of HLH and have expanded remit to include hyper-inflammation associated with COVID-19
Additional subgroups may be considered for incorporation under the CTAG umbrella as the pandemic develops.